In the latest quarter, 7 analysts provided ratings for Madrigal Pharmaceuticals (NASDAQ: MDGL), showcasing a mix of bullish and bearish perspectives.

Fintel reports that on September 29, 2025, B. Riley Securities maintained coverage of Madrigal Pharmaceuticals (NasdaqGS:MDGL ...

B. Riley raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $560 from $460 and keeps a Buy rating on the shares following a ...

Discover why MDGL's Rezdiffra leads in MASH therapy with rapid US and EU expansion. Learn about growth potential and risks.

Shares of Madrigal Pharmaceuticals (NASDAQ: MDGL) were soaring 15.2% higher as of 11:05 a.m. ET on Wednesday. The big gain came after the small biopharmaceutical company announced its fourth-quarter ...

License agreement supports Madrigal’s pipeline strategy to develop innovative combination treatments for MASH, anchored by its foundational therapy Rezdiffra™ (resmetirom) Combining Rezdiffra with the ...

Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with ...

CONSHOHOCKEN, Pa., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated ...

CONSHOHOCKEN, Pa., July 30, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) (“Madrigal”) today announced that it has entered into an exclusive global license agreement with CSPC ...

First-quarter 2025 Rezdiffra™ (resmetirom) net sales of $137.3 million As of March 31, 2025, more than 17,000 patients on Rezdiffra Two-year compensated MASH cirrhosis (F4c) data from MAESTRO-NAFLD-1 ...

CONSHOHOCKEN, Pa., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic ...